Background: Human serum paraoxonase-1 (PON1) is a high-density lipoprotein-associated ester hydrolase which can inhibit low-density lipoprotein oxidation and has an antiatherogenic effect. Two common polymorphisms are known in the PON1 gene in humans (at positions 55 and 192), from which the latter gene alteration has been mainly attributed to alter the activity of the protein. Moreover, significantly reduced PON1 activity was found in chronic kidney disease (CKD) and renal transplant patients. Methods: The aim of the present study was to investigate the genotype and phenotype distribution of the PON1 gene as well as its end product activity in patients with CKD (n = 117), in renal transplant recipients (n = 146) and in reference subjects (n = 1,180). Results: Unexpectedly high discordances between phenotype and genotype assessments were observed in all studied groups (28.2% in the CKD, 20.55% in the transplant and 30.9% in the reference group). Arylesterase activity was significantly lower in the CKD group compared to the reference sample. There were no significant differences between patients and the reference group in the frequencies of polymorphisms PON1–55 and PON1–192. PON1 activity did not differ in patients compared to the reference group. Conclusions: Both PON1 phenotype and genotype determinations are necessary to estimate PON1 status.

Keywords:
Paraoxonase, Phenotype, Genotype, Renal failure, Renal transplantation, Dyslipidemia
1.
Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(suppl 3):S112–S119.
2.
Mackness B, Durrington PN, Macness MI: Human serum paraoxonase. Gen Pharmacol 1998;31:329–336.
3.
La Du BN, Eckerson HW: The polymorphic paraoxonase/aryl-esterase isoenzymes of human serum. Fed Proc 1984;43:2338–2341.
4.
Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C: Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998;9:2082–2088.
5.
Dirican M, Akca R, Sarandol E, Dilek K: Serum paraoxonase activity in uremic predialysis and haemodialysis patients. J Nephrol 2004;17:813–818.
6.
Gülcin A, Özgönül M, Sözmen EZ, Aslan SL, Sözmen B: Renal cortical thickness and PON1 activity both decrease in chronic renal failure. J Nephrol 2002;15:144–149.
7.
Hasselwander O, McMaster D, Fogarty DG, Maxwell AP, Nicholls DP, Young IS: Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998;44:179–181.
8.
Itahara T, Suehiro T, Ikeda Y, Inoue M, Nakamura T, Kumon Y, Kawada M, Hashimoto K: Serum paraoxonase and aryl-esterase activities in haemodialysis patients. J Atheroscler Thromb 2000;7:152–158.
9.
Paragh G, Asztalos L, Seres I, Balogh Z, Löcsey L, Kárpáti I, Mátyus J, Katona E, Harangi M, Kakuk G: Serum paraoxonase activity changes in uremic and kidney transplanted patients. Nephron 1999;83:126–131.
10.
Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G: Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996;247:71–80.
11.
Schiavon R, Battaglia P, De Fanti E, Fasolin A, Biasioli S, Targa L, Guidi G: HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002;324:39–44.
12.
Suehiro T, Ikeda Y, Shiinoki T, Kumon Y, Ithara T, Hasimoto K: Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 2002;9:133–138.
13.
Ferretti G, Bacchetti T, Masciangelo S, Pallotta G: Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 2008;41:381–386.
14.
Dirican M, Sarandol E, Serdar Z, Ocak N, Dilek K: Oxidative status and prevalent cardiovascular disease in patients with chronic renal failure treated by hemodialysis. Clin Nephrol 2007;68:144–150.
15.
Ikeda Y, Suehiro T, Itahara T, Inui Y, Chikazawa H, Inoue M, Arii K, Hashimoto K: Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 2007;67:358–365.
16.
Vincent-Viry M, Sass C, Bastien S, Aguillon D, Siest G, Visvikis S: PON1–192 phenotype and genotype assessments in 918 subjects of the Stanislas Cohort Study. Clin Chem Lab Med 2003;41:535–540.
17.
Szeles G, Voko Z, Jenei T, Kardos L, Pocsai Z, Bajtay A, Papp E, Pásti G, Kósa Z, Molnár I, Lun K, Adány R: A preliminary evaluation of a health monitoring programme in Hungary. Eur J Public Health 2005;15:26–32.
18.
Pocsai Z, Toth Z, Paragh G, Szeles G, Adany R: Rapid genotyping of paraoxonase 55 and 192 mutations by melting point analysis using real time PCR technology. Clin Chim Acta 2003;33:231–236.
19.
Akhmedova SN, Yakimovsky AK, Schwartz EI: Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson’s disease. J Neurol Sci 2001;184:179–182.
20.
Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451–1457.
21.
Brophy V, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE: Promoter polymorphism effects on paraoxonase (PON1) expression. Am J Hum Genet 2001;68:1428–1436.
22.
Covic A, Gusbeth-Tatomir P, Goldsmith DJA: The challenge of cardiovascular risk factors in end-stage renal disease. J Nephrol 2003;16:476–486.
23.
Kalogerakis G, Baker AM, Chrisov S, Rowley KG, Dwyer K, Winterbourn C, Best JD, Jenkins AJ: Oxidative stress and high-density lipoprotein function in type I diabetes and end-stage renal disease. Clin Sci 2005;108:497–506.
24.
van Himbergen TM, Roest M, de Graaf J, Jansen EH, Hattori H, Kastelein JJ, Voorbij HA, Stalenhoef AF, van Tits LJ: Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 2005;46:445–451.
25.
Agachan B, Yimlaz H, Isbir T, Akoglu E: Paraoxonase 192 polymorphism and its relationship to serum lipids in Turkish renal transplant recipients. Transplant Proc 2004;36:1385–1386.
26.
Abraham P, Sugumar E: Enhanced PON1 activity in the kidneys of cyclophosphamide treated rats may play a protective role as an antioxidant against cyclophosphamide induced oxidative stress. Arch Toxicol 2008;82:237–238.
27.
Roest M, van Himbergen TM, Barendrecht AB, Peeters PHM, van der Schouw YT, Voorbij HAM: Genetic and environmental determinants of the PON-I phenotype. Eur J Clin Invest 2007;37:187–196.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.